近期,光源伙伴「Adcentrx Therapeutics 」公司再次取得重大进展。其针对晚期实体瘤的 Nectin-4 ADC 候选产品 ADRX-0706 ...
During the event, Sutro announced three planned IND filings over the next three years for wholly owned programs, including STRO-004, a tissue-factor targeting ADC, featuring a DAR8 exatecan ...